Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
agatolimod
- Development stage
- Phase 2
- Lead developer
- Pfizer
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous, Intravenous, Intratumoral, Topical
01
Overview
Agatolimod is a synthetic 24-mer oligonucleotide containing unmethylated CpG motifs, designed as an immunostimulatory agent. It acts as a Toll-like receptor 9 (TLR9) agonist, selectively targeting TLR9 to activate dendritic and B cells, thereby stimulating cytotoxic T cell and antibody responses against tumor antigens. Agatolimod has been investigated primarily for its potential antineoplastic and immunomodulatory effects in cancer therapy, but has also been studied for infectious diseases, allergies, and asthma. The drug was originally developed by Coley Pharmaceutical Group and later acquired by Pfizer[1][2][4][5][7].
- Brand names
- ProMune
- Other names
- agatolimod sodiumVaxImmune
02
Targets
TLR9 (Toll-like receptor 9)
Beyond the preview
Go deeper on agatolimod.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on agatolimod.